ArticleCancer biology & medicine2019
Current applications and future prospects of nanotechnology in cancer immunotherapy.
Article in Cancer biology & medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.
- Application of nanoparticles in breast cancer treatment: a systematic review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Pooled it
- Nanomaterials in gene therapy and genome editing: challenges and emerging directions.Journal of nanobiotechnology · 2025Review
- Advances in mechanisms and challenges in clinical translation of synergistic nanomaterial-based therapies for melanoma.Frontiers in cell and developmental biology · 2025Review
- A Spotlight on PLGA-based Nanoparticles: Pioneering a New Era in the Therapeutics of Cardiovascular Disorders.Current pharmaceutical design · 2025Review
- Micropeptides Encoded by Noncoding RNAs: Biological Functions and Roles in Diseases.Research (Washington, D.C.) · 2025Review
- Aptamer-functionalized nanomaterials (AFNs) for therapeutic management of hepatocellular carcinoma.Journal of nanobiotechnology · 2024Review
- Human serum albumin as the carrier to fabricate STING-activating peptide nanovaccine for antitumor immunotherapy.Materials today. Bio · 2024Article
- Nanomedicines: Emerging Platforms in Smart Chemotherapy Treatment-A Recent Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Trends and Patterns in Mandible Bone Cancer Research: An Updated Comprehensive Bibliometric Review : Prevalence of Supernumerary Teeth in Patients with Cleft lip and Palate.Galen medical journal · 2024Article
- Engineered cell-based therapies in ex vivo ready-made CellDex capsules have therapeutic efficacy in solid tumors.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- Biodegradable MnOMaterials today. Bio · 2023Article
- Phosphorothioated amino-AS1411 aptamer functionalized stealth nanoliposome accelerates bio-therapeutic threshold of apigenin in neoplastic rat liver: a mechanistic approach.Journal of nanobiotechnology · 2023Article
- Nanomaterials in tuberculosis DNA vaccine delivery: historical perspective and current landscape.Drug delivery · 2022Review
- mRNA cancer vaccines: Advances, trends and challenges.Acta pharmaceutica Sinica. B · 2022Review
- Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy.Exploration (Beijing, China) · 2022Review
- Melanin and Melanin-Functionalized Nanoparticles as Promising Tools in Cancer Research-A Review.Cancers · 2022Review
- Nanotechnology-based products for cancer immunotherapy.Molecular biology reports · 2022Review
- Combining Nanocarrier-Assisted Delivery of Molecules and Radiotherapy.Pharmaceutics · 2022Review
- Iron oxide nanoparticles for immune cell labeling and cancer immunotherapy.Nanoscale horizons · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer immunotherapy is an artificial stimulation of the immune system to recognize cancer cells and activate specific immune cells to target and attack cancer cells. In clinical trials, immunotherapy has recently shown impressive results in the treatment of multiple cancers. Thus, cancer immunotherapy has gained a lot of attention for its unique advantages and promising future. With extensive research on cancer immunotherapy, its safety and effectiveness has gradually been revealed. However, it is still a huge challenge to expand and drive this therapy while maintaining low toxicity, high specificity, and long-lasting efficacy. As a unique technology, nanotechnology has been applied in many fields, the advantages of which will promote the development of cancer immunotherapies. Researchers have tried to apply nanomaterials to cancer immunotherapy due to their advantageous properties, such as large specific surface areas, effective drug delivery, and controlled surface chemistry, to improve treatment efficacy. Here, we briefly introduce the current applications of nanomaterials in cancer immunotherapy, including adoptive cell therapy (ACT), therapeutic cancer vaccines, and monoclonal antibodies, and throw light on future directions of nanotechnology-based cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.